Unbiased News Awaits.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Heatwaves
World Cup
Artificial Intelligence
Social Media
Donald Trump
Immigration
Education
Property
Basketball
Soccer
Natural Disasters
European Union
Published • loading... • Updated

Phase 2B ExTINGUISH Trial Aims to Assess Efficacy of Inebilizumab for NMDAR Encephalitis

Summary by neurologylive.com
The ExTINGUISH trial investigates inebilizumab's efficacy for NMDAR encephalitis, aiming to enhance treatment options for diverse patient populations.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
neurologylive.comneurologylive.com

Phase 2B ExTINGUISH Trial Aims to Assess Efficacy of Inebilizumab for NMDAR Encephalitis

The ExTINGUISH trial investigates inebilizumab's efficacy for NMDAR encephalitis, aiming to enhance treatment options for diverse patient populations.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Tuesday, June 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal